Pembrolizumab receives FDA approval for people with early-stage, triple-negative breast cancer
https://www.facingourrisk.org/XRAY/pembrolizumab-for-triple-negative-breast-cancer
Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1910549
The FDA approved the immunotherapy drug pembrolizumab (Keytruda) for the treatment of early-stage triple-negative breast cancer that has a high risk for recurrence. This marks the first approval for this type of drug, known as an immune checkpoint inhibitor, for the treatment of early-stage breast cancer. (posted 9/2/21)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Is Keytruda a treatment option for my type of breast cancer?
- If Keytruda is not an option for me now, might it be an option in the future?
- What side effects might I experience with this treatment?
- If I have serious side effects, will I need to stop treatment?
- Are any other drugs available to treat my cancer?
- Should my tumor be genetically tested to see if there are other treatments my cancer may respond to?
Open Clinical Trials
The following studies are enrolling people with early-stage TNBC.
- NCT05629585: A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03). This study evaluates the safety and effectiveness of the investigational drug Dato-DXd given with or without durvalumab when compared with the combination capecitabine and/or pembrolizumab in people with stage 1-3 TNBC who have residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
- NCT04584255: Treating Early-Stage BRCA, or PALB2-Associated Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab). This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA mutations.
- NCT03562637: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC. The GLORIA study is a Phase III, randomized trial investigating the use of the drug adagloxad simolenin (OBI-822) in combination with the drug OBI-821 for adjuvant treatment of patients with high-risk, early-stage TNBC.
- NCT05455658: STEMVAC in Patients With Early Stage Triple Negative Breast Cancer. This trial studies the effect of the STEMVAC vaccine to treat patients with patients with stage 2B-3 triple-negative breast cancer.
- NCT05929768: Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer. This study compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to the standard chemo-immunotherapy for the treatment of early-stage triple-negative breast cancer.
Several other clinical trials for patients with early-stage TNBC can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.